Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

liraglutide

Sanofi reception

Sanofi taps Evotec for new anti-infectives drive

The duo will set up the initiative at Sanofi’s R&D unit in France

Sanofi ponders which African health tech start-ups to bring to Paris

It's on the look out for those working in non-communicable diseases, telemedicine and HCP education

- PMLiVE

Novo launches $165m antimicrobial resistance initiative

The REPAIR Fund will support groups looking to combat antibiotic resistance

- PMLiVE

Novo’s oral semaglutide ‘safe and well-tolerated’

Releases first phase III data on the new version of its diabetes treatment

- PMLiVE

Smart watch epilepsy monitor cleared by FDA

Approval could potentially clear the way for insurers to reimburse its cost

dengue fever mosquito

Takeda gets FDA fast-track status for Zika vaccine

The phase I candidate also has the backing of US federal funding body BARDA

Sanofi reception

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

The offer comes at a 110% premium on the Belgian biopharma’s share price

- PMLiVE

Dominique Carouge joins Sanofi as head of business transformation

He also becomes a member of the executive committee

Sanofi reception

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

French pharma firm offers $105 apiece for the spin-out’s shares

Sanofi reception

Sanofi and Regeneron ramp up immuno-oncology collaboration

Will put an additional $1bn in investigational candidate cemiplimab

- PMLiVE

Ablynx knocks-back Novo Nordisk’s second bid

Says the Danish pharma group “fundamentally undervalues” the company

- PMLiVE

Novo Nordisk makes improved €2.6bn offer for Ablynx

Goes back to the Belgian biopharma with a higher bid

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links